Cancer Genetics Priced, OTC: CGIX
Offers personalized genomic tests to improve the diagnosis and treatment of cancer.
Industry: Health Care
First Day Return: +12.5%
Industry: Health Care
CGIX
Offers personalized genomic tests to improve the diagnosis and treatment of cancer.
| IPO Data | |
|---|---|
| IPO File Date | 12/30/2011 |
| Offer Price | $10.00 |
| Price Range $10.00 - $12.00 | |
| Offer Shares (mm) | 0.6 |
| Deal Size ($mm) | $6 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 04/04/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $6 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Rutherford, NJ, United States |
| Founded | 1999 |
| Employees at IPO | 47 |
| Website www.cancergenetics.com | |
IPO News for Cancer Genetics
Cancer Genetics (CGIX) Performance
